Skip to content

China SXT Pharmaceuticals, Inc.

SXTC

CIK 0001723980

← back to feed
Revenue (TTM)
$1.93M
−2.2% YoY FY Mar 2025
Net Income (TTM)
−$3.3M
−6.6% YoY FY Mar 2025
EPS Diluted (TTM)
−$2.32
+91.9% YoY FY Mar 2025
Gross Margin
19.1%
FY Mar 2025
Operating Margin
-139.0%
FY Mar 2025
Net Margin
-171.3%
FY Mar 2025
Free Cash Flow (TTM)
−$2.48M
FY Mar 2025
Cash
$18.1M
FY Mar 2025
Total Debt
$798.45K
FY Mar 2025
Shares Outstanding
0 sh
FY Mar 2025

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings